Synthetic Modulators of the Vitamin D Receptor: From Structural Innovation to Disease-Specific Applications

Area of Science:

• Endocrinology and Molecular Biology
• Medicinal Chemistry
• Pharmacology

Background:

• Vitamin D receptor (VDR) signaling is crucial for calcium-phosphate balance and regulates key cellular processes.
• The natural VDR agonist, 1α,25-dihydroxyvitamin D₃ (calcitriol), has limited use for non-skeletal conditions due to hypercalcemia.
• Understanding VDR-ligand interactions is key to developing safer therapeutics.

Purpose of the Study:

• To review VDR biology and the structural basis of VDR ligand action.
• To highlight strategies for engineering selective VDR modulators (SVRMs).
• To discuss the therapeutic potential of VDR targeting in various diseases.

Main Methods:

• Review of VDR biology, structural mechanisms of ligand binding, and medicinal chemistry approaches.
• Analysis of secosteroidal and non-seco VDR ligand scaffolds.
• Examination of clinical and experimental VDR-targeting agents.

Main Results:

• Ligand-induced repositioning of helix 12 and altered coregulator recruitment are key to VDR modulation.
• Medicinal chemistry strategies have yielded diverse VDR ligand analogs.
• Evidence supports VDR targeting in cancer, metabolic, fibrotic, and inflammatory diseases.

Conclusions:

• Next-generation VDR ligands, informed by structural and epigenomic data, show promise as tissue- and pathway-biased therapeutics.
• Selective VDR modulators may enable safer clinical translation for extraskeletal indications.
• Overcoming resistance mechanisms is crucial for VDR-targeted therapies.